Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mentoring | 1 | 2023 | 85 | 0.700 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 177 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2026 | 1336 | 0.490 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 2 | 2025 | 9 | 0.440 |
Why?
|
| Internship and Residency | 2 | 2023 | 1223 | 0.400 |
Why?
|
| Smoldering Multiple Myeloma | 2 | 2024 | 3 | 0.390 |
Why?
|
| Sulfonamides | 2 | 2026 | 296 | 0.340 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 421 | 0.340 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 269 | 0.320 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2026 | 151 | 0.310 |
Why?
|
| Azacitidine | 2 | 2026 | 52 | 0.300 |
Why?
|
| Emergency Medical Services | 2 | 2022 | 352 | 0.300 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2026 | 18 | 0.240 |
Why?
|
| Phosphatidylcholines | 1 | 2026 | 34 | 0.240 |
Why?
|
| Bayes Theorem | 2 | 2024 | 311 | 0.240 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2026 | 73 | 0.230 |
Why?
|
| Beekeeping | 1 | 2025 | 1 | 0.230 |
Why?
|
| Colony Collapse | 1 | 2025 | 1 | 0.230 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2026 | 57 | 0.230 |
Why?
|
| Prostate-Specific Antigen | 2 | 2018 | 224 | 0.230 |
Why?
|
| Hydrogen Sulfide | 1 | 2024 | 8 | 0.220 |
Why?
|
| Salvage Therapy | 1 | 2026 | 174 | 0.220 |
Why?
|
| Varenicline | 1 | 2024 | 12 | 0.220 |
Why?
|
| Golgi Apparatus | 1 | 2024 | 92 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2024 | 483 | 0.210 |
Why?
|
| Camping | 1 | 2004 | 14 | 0.200 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 1419 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2026 | 713 | 0.200 |
Why?
|
| Mass Screening | 3 | 2024 | 822 | 0.190 |
Why?
|
| Smoking Cessation | 1 | 2024 | 191 | 0.190 |
Why?
|
| Age of Onset | 1 | 2024 | 592 | 0.190 |
Why?
|
| Aged | 16 | 2026 | 21025 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 889 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 113 | 0.180 |
Why?
|
| Faculty | 1 | 2023 | 99 | 0.180 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 2602 | 0.180 |
Why?
|
| Oligopeptides | 2 | 2021 | 101 | 0.180 |
Why?
|
| Advance Care Planning | 1 | 2022 | 43 | 0.180 |
Why?
|
| Communication | 2 | 2023 | 543 | 0.180 |
Why?
|
| Maternal-Fetal Relations | 1 | 2021 | 19 | 0.180 |
Why?
|
| Humans | 31 | 2026 | 131163 | 0.170 |
Why?
|
| Parturition | 1 | 2021 | 65 | 0.170 |
Why?
|
| Dexamethasone | 2 | 2021 | 250 | 0.170 |
Why?
|
| Indazoles | 1 | 2020 | 35 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2024 | 674 | 0.160 |
Why?
|
| Software | 1 | 2025 | 733 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2020 | 80 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2026 | 694 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2025 | 1833 | 0.160 |
Why?
|
| Curriculum | 2 | 2023 | 798 | 0.160 |
Why?
|
| Middle Aged | 15 | 2026 | 28601 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 1 | 2025 | 1692 | 0.150 |
Why?
|
| Vagina | 1 | 2021 | 208 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2026 | 614 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2026 | 1077 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 394 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 124 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 237 | 0.150 |
Why?
|
| Football | 1 | 2019 | 39 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 496 | 0.140 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 132 | 0.140 |
Why?
|
| Teaching Rounds | 1 | 2018 | 30 | 0.140 |
Why?
|
| Heart Conduction System | 1 | 2019 | 164 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 621 | 0.130 |
Why?
|
| Female | 19 | 2026 | 70963 | 0.130 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 258 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2020 | 446 | 0.130 |
Why?
|
| Adult | 12 | 2026 | 31282 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 149 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2026 | 1280 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 570 | 0.120 |
Why?
|
| Male | 17 | 2026 | 64957 | 0.120 |
Why?
|
| Biomarkers | 1 | 2026 | 3385 | 0.120 |
Why?
|
| Genomics | 1 | 2024 | 1621 | 0.120 |
Why?
|
| Microbiota | 1 | 2021 | 438 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2026 | 6797 | 0.120 |
Why?
|
| Lymphoma, Follicular | 1 | 2016 | 29 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1722 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 75 | 0.120 |
Why?
|
| Simulation Training | 1 | 2018 | 153 | 0.110 |
Why?
|
| Parents | 1 | 2023 | 1128 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1586 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2833 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 119 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2016 | 317 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3436 | 0.100 |
Why?
|
| Medical Records | 1 | 2015 | 174 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 842 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 307 | 0.100 |
Why?
|
| Mutation | 2 | 2024 | 6099 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2019 | 1559 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 738 | 0.090 |
Why?
|
| Young Adult | 5 | 2026 | 10103 | 0.080 |
Why?
|
| Child | 3 | 2026 | 26341 | 0.070 |
Why?
|
| Pediatrics | 1 | 2018 | 1252 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 4066 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2026 | 3748 | 0.070 |
Why?
|
| Transcriptome | 2 | 2025 | 1103 | 0.060 |
Why?
|
| Ifosfamide | 1 | 2026 | 26 | 0.060 |
Why?
|
| Sphingosine | 1 | 2026 | 23 | 0.060 |
Why?
|
| Carboplatin | 1 | 2026 | 79 | 0.060 |
Why?
|
| Etoposide | 1 | 2026 | 112 | 0.060 |
Why?
|
| Lysophospholipids | 1 | 2026 | 45 | 0.060 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2026 | 22 | 0.060 |
Why?
|
| Varroidae | 1 | 2025 | 1 | 0.060 |
Why?
|
| United Kingdom | 2 | 2018 | 267 | 0.060 |
Why?
|
| Adolescent | 4 | 2026 | 20987 | 0.060 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2026 | 52 | 0.060 |
Why?
|
| Bees | 1 | 2025 | 26 | 0.060 |
Why?
|
| United States | 4 | 2025 | 12072 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1118 | 0.060 |
Why?
|
| Rituximab | 1 | 2026 | 170 | 0.060 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2024 | 14 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2026 | 4738 | 0.050 |
Why?
|
| Michigan | 1 | 2004 | 47 | 0.050 |
Why?
|
| Binomial Distribution | 1 | 2023 | 5 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 39 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2026 | 711 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2026 | 670 | 0.050 |
Why?
|
| Kentucky | 1 | 2023 | 29 | 0.050 |
Why?
|
| Animals | 4 | 2026 | 33912 | 0.050 |
Why?
|
| Cause of Death | 2 | 2016 | 506 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3829 | 0.050 |
Why?
|
| Mice | 3 | 2026 | 18301 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 259 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 362 | 0.050 |
Why?
|
| Recurrence | 1 | 2026 | 1489 | 0.050 |
Why?
|
| Chromatin | 1 | 2025 | 499 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2024 | 928 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2022 | 88 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2026 | 1246 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2085 | 0.040 |
Why?
|
| Risk Factors | 2 | 2026 | 11074 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2026 | 6459 | 0.040 |
Why?
|
| Computational Biology | 1 | 2025 | 862 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1490 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 258 | 0.040 |
Why?
|
| Age Factors | 1 | 2026 | 2825 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 768 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5196 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2026 | 1928 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2022 | 730 | 0.030 |
Why?
|
| Genotype | 1 | 2024 | 2595 | 0.030 |
Why?
|
| Vaccination | 1 | 2024 | 1060 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2021 | 1021 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2021 | 426 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 136 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 306 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 99 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 1801 | 0.030 |
Why?
|
| Focus Groups | 1 | 2018 | 239 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2019 | 729 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 344 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 422 | 0.030 |
Why?
|
| Death Certificates | 1 | 2016 | 10 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 1445 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1680 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 400 | 0.030 |
Why?
|
| Social Class | 1 | 2018 | 214 | 0.030 |
Why?
|
| Incidence | 1 | 2023 | 3360 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2004 | 1224 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 123 | 0.030 |
Why?
|
| South Carolina | 1 | 2015 | 10 | 0.030 |
Why?
|
| General Practitioners | 1 | 2015 | 18 | 0.030 |
Why?
|
| Mastectomy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Phenotype | 1 | 2024 | 4497 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 231 | 0.030 |
Why?
|
| Prostate | 1 | 2016 | 404 | 0.030 |
Why?
|
| Time Factors | 1 | 2004 | 6196 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 821 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2026 | 17753 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1029 | 0.020 |
Why?
|
| Brain | 1 | 2025 | 3175 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 713 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 2701 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 555 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 722 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1272 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2018 | 775 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 915 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 716 | 0.020 |
Why?
|
| Infant | 1 | 2026 | 13352 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2026 | 15110 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7512 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 12936 | 0.010 |
Why?
|